Absorption, Distribution, Metabolism and Excretion of [14C]- Labeled BIA 5-453 and Metabolites

NCT03014375 | Completed Phase 1

• 1 other identifier: BIA-5453-103
• Study Type: interventional
• Target: 4
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to: To determine the rate and routes of excretion of BIA 5-453 and the mass balance in urine and faeces

Conditions

Hypertension; Congestive Heart Failure

Outcome Measures

Primary Outcomes (3)

• urinary excretion of BIA 5-453 associated radioactivity

  following a single 600 mg oral dose labeled with 98 μCi of \[14C\]

  pre-dose, then it was collected from 0-4, 4-8, 8-24, 24-48, 48-72, 72-120, 120-168, 168-216, and 216-264 hours post-dose.

• faecal excretion of BIA 5-453 associated radioactivity

  baseline period. Following dose, each faeces sample was collected during the 264 hours post-dose period.

  following a single 600 mg oral dose labeled with 98 μCi of [14C]

• amount of BIA 5-453 associated radioactivity present in the expired air

  following a single 600 mg oral dose labeled with 98 μCi of \[14C\]

  baseline, 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 4h 6h, 8h, 12h and 24h post-dose

Study Arms (1)

Etamicastat

EXPERIMENTAL

Single administration. 100 μCi/ 3.7 MBq 14C labeled BIA 5-453 50 mg, hard gelatina capsules

Drug: BIA-5-453

Interventions

BIA-5-453 DRUG

Each subject will receive a single oral dose of 100 μCi/ 3.7 MBq 14C labeled BIA 5-453 (600 mg).

Etamicastat

Eligibility Criteria

• Age: 40 Years - 55 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy Caucasian male subjects, 40-55 years of age.
• Sitting blood pressure and pulse rate within a clinically acceptable range for the purposes of the study, i.e.: BP: 100 160 mmHg systolic, 50 95 mmHg diastolic and pulse rate: 50 100 bpm. Blood pressure and pulse will be measured after 3 minutes resting in a sitting position.
• Subject body mass index must be between 18 and 28 kg/m2
• Normal 12-lead ECG
• Ability to communicate well with the investigator and comply with the requirements of the entire study.
• The subject has given his written informed consent to participate in the study.

You may not qualify if:

• History of serious adverse reactions or hypersensitivity to any drug.
• Presence or history of allergies requiring acute or chronic treatment (except seasonal allergic rhinitis).
• History of alcohol or drug abuse in the last 5 years.
• Abnormal physical findings of clinical significance at the screening examination or baseline which would interfere with the objectives of the study.
• Need of any prescription medication within 14 days prior to the administration of the drug and/or nonprescription medication within 7 days prior to the administration of the drug.
• Participation in other clinical trials during the previous month in which an investigational drug or a commercially available drug was tested.
• Loss of 500 mL blood or more during the 3 month period before the study, e.g., as a donor.
• Existence of any surgical or medical condition which might interfere with the absorption, distribution, metabolism or excretion of the drug, i.e., impaired renal or hepatic function, diabetes mellitus, cardiovascular abnormalities, chronic symptoms of pronounced constipation or diarrhoea or conditions associated with total or partial obstruction of the urinary tract.
• Symptoms of a significant somatic or mental illness in the 4 week period preceding drug administration.
• History of hepatitis B and / or C and / or positive serology results which indicate the presence of hepatitis B and / or C.
• Positive results from the HIV serology.
• Clinically significant abnormal laboratory values (as determined by the Principal Investigator) at the screening evaluation, however, liver parameters (SGPT, SGOT) values must be within the normal range.
• Positive results of the drug screening.
• Known hypersensitivity to BIA 5-453.
• Heavy smokers, i.e., more than 10 cigarettes per day

Sponsors & Collaborators

• Bial - Portela C S.A.: lead

Study Sites (1)

Swiss Pharma Contract Ltd.

Allschwil, CH-4123, Switzerland

Location

MeSH Terms

Conditions

Hypertension; Heart Failure

Interventions

etamicastat

Condition Hierarchy (Ancestors)

Vascular Diseases; Cardiovascular Diseases; Heart Diseases

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 5, 2017
• First Posted: January 9, 2017
• Study Start: September 1, 2008
• Primary Completion: October 1, 2008
• Study Completion: October 1, 2008
• Last Updated: January 9, 2017

Record last verified: 2017-01

Locations

CH (1)